The amidated PACAP_1-23 fragment is a potent reduced-size neuroprotective agent

Area of Science:

• Neuroscience
• Molecular Biology
• Pharmacology

Background:

• Neurodegenerative disorders like Parkinson's disease involve neuronal death, mitochondrial dysfunction, and excitotoxicity.
• Pituitary adenylate cyclase-activating polypeptide (PACAP) shows neuroprotective potential, crossing the blood-brain barrier.
• PACAP interacts with PAC1, VPAC1, and VPAC2 receptors; only PAC1 activation offers anti-apoptotic effects.

Purpose of the Study:

• To evaluate the neuroprotective capacity of PACAP(1-23) (PACAP23), the shortest bioactive PACAP fragment, against mitochondrial dysfunction and excitotoxicity.
• To assess PACAP23's ability to bind PACAP receptors and activate downstream signaling pathways.
• To explore PACAP23 as a template for developing novel neuroprotective agents.

Main Methods:

• Neuroblastoma cells were used to test PACAP23's neuroprotection under stress conditions.
• PACAP23's receptor binding affinity and downstream signaling (G proteins, EPAC, calcium) were assessed.
• PACAP23's neuroprotective effects and signaling were compared to full-length PACAP.

Main Results:

• PACAP23 demonstrated potent neuroprotection despite having reduced affinity for the PAC1 receptor compared to full-length PACAP.
• PACAP23 exhibited distinct downstream signaling patterns compared to full-length PACAP, indicating differential regulation.
• These findings suggest that subtle differences in PAC1 interaction influence neuroprotective signaling.

Conclusions:

• Amidated PACAP23 exhibits significant neuroprotective properties.
• PACAP23 serves as a valuable template for creating shorter, PACAP-derived neuroprotective molecules.
• Further research into PACAP23's distinct signaling could lead to targeted therapies for neurodegenerative conditions.